Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging

Radiology

Volumn 237, Issue 2, 2005, Pages 492-499

  Thoeny, Harriet C ^a,b   De Keyzer, Frederik ^a   Vandecaveye, Vincent ^a   Chen, Feng ^a   Sun, Xihe ^a   Bosmans, Hilde ^a   Hermans, Robert ^a   Verbeken, Eric K ^a   Boesch, Chris ^b   Marchal, Guy ^a   Landuyt, Willy ^c   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; GADODIAMIDE; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CELL DEATH; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HISTOPATHOLOGY; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RAT; REGRESSION ANALYSIS; RHABDOMYOSARCOMA; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TISSUE PERFUSION; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; GADOLINIUM DTPA; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAPERITONEAL; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED STRAINS; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; STILBENES;

EID: 27144541488     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2372041638     Document Type: Article

References (28)

1. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59:1626-1634.
2. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21-38.
3. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-1834.
4. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
5. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
6. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-3840.
7. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21: 2831-2842.
8. Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-1167.
9. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-2822.
10. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-2830.
11. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62: 3408-3416.
12. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-1850.
13. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-4438.
14. Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232:685-692.
15. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497-505.
16. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995; 33:564-568.
17. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
18. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234:756-764.
19. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56:607-620.
20. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003;228: 271-278.
21. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-1767.
22. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 1994;32:714-724.
23. Kremser C, Judmaier W, Hein P, Griebel J, Lukas P, de Vries A. Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 2003; 179:641-649.
24. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-308.
25. Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 1998; 206:227-235.
26. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002;21:717-726.
27. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10: 223-232.
28. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.